東方電氣(01072.HK)回購註銷共15萬股限制性股票
格隆匯1月5日丨東方電氣(01072.HK)公吿,根據《上市公司股權激勵管理辦法》及公司《2019年A股限制性股票激勵計劃(草案修訂稿)》的相關規定,首次授予的激勵對象中3人因個人原因離職而不再具備激勵對象資格,1人因違反相關法規而不再具備激勵對象資格,1人因個人績效考核不達標未滿足本激勵計劃首次授予第一期解除限售條件,董事會審議決定回購註銷上述5名激勵對象已獲授但尚未解除限售的全部限制性股票共計15萬股。
本次回購註銷完成後,公司總股本將由3,119,151,130股減少至3,119,001,130股,公司註冊資本也相應由3,119,151,130元減少為3,119,001,130元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.